Ahmadzadeh Mojgan, Johnson Laura A, Heemskerk Bianca, Wunderlich John R, Dudley Mark E, White Donald E, Rosenberg Steven A
Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Blood. 2009 Aug 20;114(8):1537-44. doi: 10.1182/blood-2008-12-195792. Epub 2009 May 7.
Tumor antigen-specific T cells are found within melanomas, yet tumors continue to grow. Although the tumor microenvironment is thought to influence the suppression of tumor-reactive T cells, the underlying mechanisms for this T-cell dysfunction are not clear. Here, we report that the majority of tumor infiltrating T lymphocytes (TIL), including MART-1/Melan-A melanoma antigen-specific CD8 T cells, predominantly expressed PD-1, in contrast to T cells in normal tissues and peripheral blood T lymphocytes (PBL). PD-1(+) TIL expressed CTLA-4 and Ki-67, markers that were not expressed by PD-1(-) TIL and T cells in the normal tissues and PBL. Moreover, PD-1(+) TIL were primarily HLA-DR(+) and CD127(-), in contrast to PD-1(-) TIL. Effector cytokine production by PD-1(+) TIL was impaired compared with PD-1(-) TIL and PBL. Collectively, the phenotypic and functional characterizations of TIL revealed a significantly higher frequency and level of PD-1 expression on TIL compared with normal tissue T-cell infiltrates and PBL, and PD-1 expression correlated with an exhausted phenotype and impaired effector function. These findings suggest that the tumor microenvironment can lead to up-regulation of PD-1 on tumor-reactive T cells and contribute to impaired antitumor immune responses.
在黑色素瘤中可发现肿瘤抗原特异性T细胞,但肿瘤仍持续生长。尽管肿瘤微环境被认为会影响肿瘤反应性T细胞的抑制作用,但其导致T细胞功能障碍的潜在机制尚不清楚。在此,我们报告,与正常组织中的T细胞和外周血T淋巴细胞(PBL)相比,包括MART-1/黑色素A黑色素瘤抗原特异性CD8 T细胞在内的大多数肿瘤浸润性T淋巴细胞(TIL)主要表达程序性死亡受体1(PD-1)。与正常组织和PBL中的PD-1(-)T细胞和T细胞不同,PD-1(+)TIL表达细胞毒性T淋巴细胞相关抗原4(CTLA-4)和Ki-67,而PD-1(-)TIL以及正常组织和PBL中的T细胞不表达这些标志物。此外,与PD-1(-)TIL相比,PD-1(+)TIL主要为人类白细胞抗原DR(HLA-DR)阳性和CD127阴性。与PD-1(-)TIL和PBL相比,PD-1(+)TIL产生效应细胞因子的能力受损。总体而言,TIL的表型和功能特征显示,与正常组织T细胞浸润和PBL相比,TIL上PD-1表达的频率和水平显著更高,且PD-1表达与耗竭表型和效应功能受损相关。这些发现表明,肿瘤微环境可导致肿瘤反应性T细胞上PD-1上调,并导致抗肿瘤免疫反应受损。